| scholarly article | Q13442814 |
| P2093 | author name string | Christian L Lorson | |
| Virginia B Mattis | |||
| Matthew E R Butchbach | |||
| P2860 | cites work | Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism | Q24613087 |
| Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy | Q28177632 | ||
| Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy | Q28201294 | ||
| An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA | Q28204816 | ||
| Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients | Q28209134 | ||
| The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells | Q28242279 | ||
| Induction of full-length survival motor neuron by polyphenol botanical compounds | Q28254983 | ||
| Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts | Q28261807 | ||
| Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells | Q28264072 | ||
| Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy | Q28289793 | ||
| Identification and characterization of a spinal muscular atrophy-determining gene | Q29547495 | ||
| A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy | Q29617367 | ||
| A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy | Q30488346 | ||
| A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. | Q33864982 | ||
| Treatment of spinal muscular atrophy by sodium butyrate | Q33933841 | ||
| Animal models of spinal muscular atrophy | Q34045913 | ||
| Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy | Q34353103 | ||
| The survival motor neuron protein in spinal muscular atrophy | Q34435656 | ||
| Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number | Q35250646 | ||
| Identification of a novel cyclic AMP-response element (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron (SMN) gene | Q35567374 | ||
| Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. | Q35943896 | ||
| A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. | Q36323111 | ||
| Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease | Q36347017 | ||
| Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos | Q36578997 | ||
| Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy | Q37236684 | ||
| Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. | Q38297672 | ||
| Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. | Q38325235 | ||
| Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. | Q40022982 | ||
| Valproic acid increases SMN levels in spinal muscular atrophy patient cells. | Q40620622 | ||
| Correlation between severity and SMN protein level in spinal muscular atrophy | Q41102726 | ||
| The neurobiology of childhood spinal muscular atrophy. | Q41489423 | ||
| The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy | Q43569750 | ||
| A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels | Q46404171 | ||
| In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy | Q48485610 | ||
| International SMA consortium meeting. (26-28 June 1992, Bonn, Germany) | Q67481178 | ||
| Animal models of spinal muscular atrophy | Q80970001 | ||
| SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN | Q81385781 | ||
| P433 | issue | 1 | |
| P921 | main subject | spinal muscular atrophy | Q580290 |
| P304 | page(s) | 36-43 | |
| P577 | publication date | 2008-08-15 | |
| P1433 | published in | Journal of Neuroscience Methods | Q15764020 |
| P1476 | title | Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy | |
| P478 | volume | 175 |
| Q39350652 | A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice |
| Q36079719 | Antisense-mediated exon inclusion |
| Q34082155 | Assays for the identification and prioritization of drug candidates for spinal muscular atrophy |
| Q30492560 | Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy |
| Q34760255 | Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds |
| Q39549155 | Generation of a tamoxifen inducible SMN mouse for temporal SMN replacement |
| Q34123129 | Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. |
| Q38006384 | Mouse models of SMA: tools for disease characterization and therapeutic development |
| Q34065993 | Splicing of the Survival Motor Neuron genes and implications for treatment of SMA |
| Q41683448 | Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy |
Search more.